Connect with us

Spread & Containment

Enzolytics Inc (OTCMKTS: ENZC) Powerful Reversal Underway as Immune™ Goes International in Booming Nutritional Supplement Market

Enzolytics Inc (OTCMKTS: ENZC) is making a powerful move up the charts in recent days since reversing off $0.06 support levels, the second time it has…

Published

on

Enzolytics Inc (OTCMKTS: ENZC) is making a powerful move up the charts in recent days since reversing off $0.06 support levels, the second time it has tested the $0.06 over the past month. ENZC is a major league runner and powerhouse stock and was among the biggest runners of spring 2021 making a legendary run to highs of 0.958 per share as it completed the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19 and HIV. ENZC is one of the top most traded stocks on the OTCBB and has some of its biggest players behind it looking for another legendary breakout from current levels. 

Dr. Gaurav Chandra of ENZC recently joined the Stock Day Podcast to discuss the biotech’s revenue potential among others things. Dr. Chandra made some important points stating “While we have already launched IPF Immune in the United States, we are also launching the product in Europe and Canada in the next three months.” IPF Immune has shown positive results during testing against the CoronaVirus (SARS-CoV-2) strain 229e as well as Adenovirus another booming market. The Company’s monoclonal antibody program is progressing rapidly: “We have identified the conserved immutable targets in about 20 viruses” said. Dr. Chandra, “and then we went a bit further. We built AI-based three-dimensional models of these immutable targets and established linearity, neutralization by antibodies or accessibility by antibodies, before moving forward to develop monoclonal antibodies that target these specific sequences. We actually did the same thing for HIV viruses. We identified 8 conserved immutable targets. The virus can mutate many times, but since these are conserved it will remain unchanged. The resulting monoclonal antibodies that we have created are universal, durable, broadly utilizing, and will remain unaffected by mutations or virus escape.” Dr. Chandra. also discussed the global monoclonal antibody market worth $144 billion. “We have four monoclonal antibodies for infectious diseases that are in clinical development as we speak.” said Dr. Chandra. “As you can imagine, although the market is not reflecting the actual market cap of the company, in the next six months to one year we anticipate a monumental shift in the position of the company as our clinical products start coming to the market.” 

Sign Up now for our 100% FREE Penny Stock Newsletter

Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. ENZC has been rapidly building up an intellectual property portfolio filing numerous patents last year. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for “Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor – Pharmaceutical Composition for Treatment.”  Since than the ENZC has filed a number of new applications. The Company recently merged with BioClonetics Immunotherapeutics, Inc., now a wholly owned subsidiary of Enzolytics; a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases. 

Microcapdaily has been reporting on the ENZC BioColnetics merger since the beginning first when it was $0.003 recenlty stating: “Enzolytics Inc (OTCMKTS: ENZC) is making an explosive move up the charts after the Company announced a progress update and more on its future plans. The Company spoke in depth of its work at Texas A&M University Institute for Preclinical Studies focused on the production of fully human monoclonal antibodies targeting multiple infectious diseases, including SARS-CoV-2 and HIV-1. Management also outlined the Company’s development of Artificial Intelligence for use in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations.  At Enzolytics’s Dallas laboratory, managed by Harry Zhabilov, the Company’s CSO who coordinates the development and the production of two of the Company’s primary therapeutics, ITV-1 and IPF Immune. Both therapeutics are produced under patents invented by Mr. Zhabilov, U.S. Patent Nos. 8,066,982, 7,479,538, and 8,309,072. ITV-1 is a therapeutic for treating individuals with HIV. It has been successfully produced and has been earlier successfully clinically tested in human trials under the Bulgarian Drug Agency requirements. The Company has also completed the production of IPF Immune, a product shown to function effectively as an immune booster. 

ENZC IPF Immune therapeutic is now entering the U.S. market. This science-backed immune modulator helps strengthen the body’s defenses against viruses or other pathogens. The product works as an immune booster that increases the ability of the immune system to fight infections by stimulating antiviral activity and helping to increase cell defense. The product supports the body’s immune system thereby enhancing recovery and reducing the recovery period after an illness. The Company is also planning to launch IFP Immune in Europe and Canada. The Company has distributorship contacts in Europe and sees tremendous added potential from foreign sales. This product enters the market as sales of American Dietary Supplements in North American reach $50.11 Billion. These sales are forecast to increase to $77.10 Billion in 2028. Enzolytics has engaged Nutritional Products International (NPI) to access this 50-billion-dollar market=Enzolytics IPF Immune will meet consumer needs due to its significant benefits. 

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

Dr. Chandra continued on the Stock Day Podcast then discussing the importance of AI-driven diagnostics. “We are discussing partnerships with diagnostic companies that have a track record of getting diagnostics tests through Regulatory approval and distributing these diagnostic tests for clinical use. As viruses mutate, the diagnostic test for them have to be modified to identify each mutant of the virus. But since the targets we have identified remain unchanged, if those target sites are used to diagnose the virus, then you have a test that is universally applicable even for mutants of the viruses.” 

Talking about AI-driven prognostics he said that there are documented studies showing better prognosis and clinical outcomes in patients with antibodies to the AI-identified conserved targets. Enzolytics is also discussing a potential partnership to develop a prognostic test that predicts immune response before receiving a vaccine or antiviral therapy. 

“Since we have the capability of identifying conserved targets, we are actually working to be a part of consortiums that are looking to prevent the next global pandemic, and that is very exciting for us. The AI platform significantly cuts down the time for our drug discovery and development. At Enzolytics, we build a product and put effort into R&D, and then we intend to partner with a larger entity, a large pharmaceutical company, that can take it through the clinical stages quickly. 

Dr. Chandra noted the significant market for each of the Company’s products. “The next product that we have is ITV-1, which is an HIV therapeutic and has actually cleared Phase III clinical trials and is preparing for introduction into two markets,” he explained. “The African market is a significant market because 65% of about 34 to 37 million HIV infected individuals live in Africa. We will also be introducing this product into Europe, and are currently awaiting certification under the European Medical Agency.” 

For more on ENZC Subscribe Right Now!

ENZC is making a powerful move up the charts in recent days since reversing off $0.06 support levels, the second time it has tested the $0.06 over the past month. ENZC is a major league runner and powerhouse stock and was among the biggest runners of spring 2021 making a legendary run to highs of 0.958 per share as it completed the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19 and HIV. ENZC could become a major player in the enormous $30 billion annual HIV market expected to reach $37 billion in the next 5 years. In a market primarily controlled by Gilead who sold $17 billion in HIV drugs last year Enzolytic’s HIV treatment is immunotherapy, not chemotherapy. One of the things that makes Enzolytic’s  ITV-1 stand out from the pack is its safety profile. ITV-1 is really a form of immunotherapy that strengthens the immune system. ENZC has real potential here, it’s a biotech right at 52 week lows, has one of the biggest audiences on the OTCQB, recent highs near $1 and is seeing significant progress with multiple upcoming catalysts in play.  Microcapdaily first reported on ENZC on September 16 just as it was taking off after closing at $0.0009 the day before. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

The post Enzolytics Inc (OTCMKTS: ENZC) Powerful Reversal Underway as Immune™ Goes International in Booming Nutritional Supplement Market first appeared on Micro Cap Daily.

Read More

Continue Reading

Government

New Hampshire Governor Vetoes Ivermectin Bill

New Hampshire Governor Vetoes Ivermectin Bill

Authored by Alice Giordano via The Epoch Times (emphasis ours),

New Hampshire’s Republican…

Published

on

New Hampshire Governor Vetoes Ivermectin Bill

Authored by Alice Giordano via The Epoch Times (emphasis ours),

New Hampshire’s Republican Gov. Chris Sununu vetoed a bill that would have made Ivermectin available without a prescription.

Ivermectin tablets packaged for human use. (Natasha Holt/The Epoch Times)

The Republican governor vetoed the bill on June 24, the same day that the U.S. Supreme Court overturned Roe v. Wade. Some fellow Republicans questioned the timing.

It certainly seemed like a convenient way to bury a veto of a bill that won support from the vast majority of Republicans in New Hampshire,” JR Hoell, co-founder of the conservative watchdog group RebuildNH, told The Epoch Times.

Hoell is a former four-term House Republican planning to seek re-election after a four-year hiatus from the the New Hampshire legislature.

Earlier this year, the New Hampshire Department of Children Youth and Family (DCYF) tried to take custody of Hoell’s 13-year old son after a nurse reported him for giving human-grade ivermectin to the teen months earlier.

Several states have introduced bills to make human-grade ivermectin available without a prescription at a brick and mortar store. Currently, it can be ordered online from another country. In April, Tennessee became the the first state to sign such a measure into law. New Hampshire lawmakers were first to introduce the idea.

Both chambers of the state’s Republican controlled legislature approved the bill.

In his statement explaining the veto, Sununu noted that there are only four other controlled medications available without a prescription in New Hampshire and that each were only made available after “rigorous reviews and vetting to ensure” before being dispensed.

“Patients should always consult their doctor before taking medications so that they are fully aware of treatment options and potential unintended consequences of taking a medication that may limit other treatment options in the future,” Sununu said in his statement.

Sununu’s statement is very similar to testimony given by Paula Minnehan, senior vice president of state government regulations for the New Hampshire Hospital Association, at hearings on the bill.

Minnehan too placed emphasis on the review that went into the four prescription medications the state made available under a standing order. They include naloxone, the generic name for Narcan, which is used to counter opioid overdoses, hormone replacement therapy drugs, and a prescription-version of the morning after pill.

It also includes a collection of smoking cessation therapy drugs like Chantix, which has been linked to suicide, depression, and other neuropsychiatric conditions. Last year, Pfizer, the leading maker of the FDA-approved drug, conducted a voluntarily recall of Chantix. Narcan has also been linked to deaths caused by severe withdrawals that have led to acute respiratory distress.

Rep. Melissa Blasek, a Republican co-sponsor of the New Hampshire ivermectin bill, told The Epoch Times, that one could veto any drug-related bill under the pretense of overdose concerns.

The reality is you can overdose on Tylenol,” she said. “Ivermectin has one of the safest track records of any drug.”

The use of human-grade ivermectin became controversial when some doctors began promoting it for the treatment and prevention of COVID-19. Government agencies including the FDA and CDC issued warnings against its use while groups like Front Line COVID-19 Critical Care Alliance (FLCCC) heavily promoted it.

Some doctors were  disciplined for prescribing human-grade ivermectin for COVID-19 including a Maine doctor whose medical license was suspended by the state.

Read more here...

Tyler Durden Thu, 06/30/2022 - 20:30

Read More

Continue Reading

Spread & Containment

Aging-US | Time makes histone H3 modifications drift in mouse liver

BUFFALO, NY- June 30, 2022 – A new research paper was published in Aging (Aging-US) on the cover of Volume 14, Issue 12, entitled, “Time makes histone…

Published

on

BUFFALO, NY- June 30, 2022 – A new research paper was published in Aging (Aging-US) on the cover of Volume 14, Issue 12, entitled, “Time makes histone H3 modifications drift in mouse liver.”

Credit: Hillje et al.

BUFFALO, NY- June 30, 2022 – A new research paper was published in Aging (Aging-US) on the cover of Volume 14, Issue 12, entitled, “Time makes histone H3 modifications drift in mouse liver.”

Aging is known to involve epigenetic histone modifications, which are associated with transcriptional changes, occurring throughout the entire lifespan of an individual.

“So far, no study discloses any drift of histone marks in mammals which is time-dependent or influenced by pro-longevity caloric restriction treatment.”

To detect the epigenetic drift of time passing, researchers—from Istituto di Ricovero e Cura a Carattere Scientifico, University of Urbino ‘Carlo Bo’, University of Milan, and University of Padua—determined the genome-wide distributions of mono- and tri-methylated lysine 4 and acetylated and tri-methylated lysine 27 of histone H3 in the livers of healthy 3, 6 and 12 months old C57BL/6 mice. 

“In this study, we used chromatin immunoprecipitation sequencing technology to acquire 108 high-resolution profiles of H3K4me3, H3K4me1, H3K27me3 and H3K27ac from the livers of mice aged between 3 months and 12 months and fed 30% caloric restriction diet (CR) or standard diet (SD).”

The comparison of different age profiles of histone H3 marks revealed global redistribution of histone H3 modifications with time, in particular in intergenic regions and near transcription start sites, as well as altered correlation between the profiles of different histone modifications. Moreover, feeding mice with caloric restriction diet, a treatment known to retard aging, reduced the extent of changes occurring during the first year of life in these genomic regions.

“In conclusion, while our data do not establish that the observed changes in H3 modification are causally involved in aging, they indicate age, buffered by caloric restriction, releases the histone H3 marking process of transcriptional suppression in gene desert regions of mouse liver genome most of which remain to be functionally understood.”

DOI: https://doi.org/10.18632/aging.204107 

Corresponding Author: Marco Giorgio – marco.giorgio@unipd.it 

Keywords: epigenetics, aging, histones, ChIP-seq, diet

Sign up for free Altmetric alerts about this article:  https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204107

About Aging-US:

Launched in 2009, Aging (Aging-US) publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Follow Aging on social media: 

  • SoundCloud – https://soundcloud.com/Aging-Us
  • Facebook – https://www.facebook.com/AgingUS/
  • Twitter – https://twitter.com/AgingJrnl
  • Instagram – https://www.instagram.com/agingjrnl/
  • YouTube – https://www.youtube.com/agingus​
  • LinkedIn – https://www.linkedin.com/company/aging/
  • Pinterest – https://www.pinterest.com/AgingUS/

For media inquiries, please contact media@impactjournals.com.

Aging (Aging-US) Journal Office
6666 E. Quaker Str., Suite 1B
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

Government

FDA asks for COVID boosters to fight Omicron’s BA.4, BA.5 subvariants

The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components…

Published

on

FDA asks for COVID boosters to fight Omicron’s BA.4, BA.5 subvariants

By Michael Erman

June 30 (Reuters) – The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.

The FDA said manufacturers would not need to change the vaccine for the primary vaccination series, saying the coming year will be “a transitional period when this modified booster vaccine may be introduced.”

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

The new booster shots would be bivalent vaccines, meaning doses would target both the original virus as well as the Omicron subvariants.

The decision follows a recommendation by the agency’s outside advisers to change the design of the shots this fall in order to combat more prevalent versions of the coronavirus. read more

BA.4 and BA.5 are now estimated to account for more than 50% of U.S. infections, according the U.S. Centers for Disease Control and Prevention, and have also become dominant elsewhere.

The FDA said in a statement on Thursday that it hoped the modified vaccines could be used in early to mid-fall.

Pfizer Inc (PFE.N) with partner BioNTech SE (22UAy.DE) and Moderna Inc (MRNA.O) have been testing versions of their vaccines modified to combat the BA.1 Omicron variant that caused the massive surge in cases last winter.

Although they have said those vaccines worked against BA.1 and the more recently circulating variants, they did see a lower immune response against BA.4 and BA.5.

The companies had already been manufacturing their BA.1 vaccines, and said on Tuesday that swapping to a BA.4/BA.5 version could slow the rollout.

Pfizer/BioNTech, which on Wednesday announced a $3.2 billion contract to supply more COVID vaccine doses to the United States, said they would have a substantial amount of BA.4/BA.5 vaccine ready for distribution by the first week of October. read more

Moderna said it would be late October or early November before it would have the newly modified vaccine ready.

Reporting by Michael Erman in New Jersey and Leroy Leo in Bengaluru; Editing by Jonathan Oatis and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Source: Reuters

Read More

Continue Reading

Trending